Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list
Enrico Costa(Brigham and Women's Hospital), Hubert G. M. Leufkens(Utrecht University), Hendrika A. van den Ham(Utrecht University)
Cited by 2
Related Papers
Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications
|European Journal of Clinical Pharmacology|2014|162
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
Antibiotic prescribing for children in primary care and adherence to treatment guidelines
|Journal of Antimicrobial Chemotherapy|2016|74
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
|Orphanet Journal of Rare Diseases|2022|51